Noom Prescription and Intake Process: What Actually Happens Step by Step

What Is Noom's Business Model and Is It a Legitimate Medical Service?

Noom is a legitimate, FDA-registered telehealth platform, but it is not a traditional clinical practice. The core product is a smartphone app built around cognitive behavioral principles for weight management. The GLP-1 prescribing layer, branded "Noom Med," is an add-on service staffed by licensed clinicians operating under standard telehealth regulations.

The behavioral-coaching framework Noom uses is grounded in evidence. A randomized controlled trial published in BMJ Open found that app-based behavioral interventions produced modest but statistically significant weight loss compared to control, though effect sizes were smaller than those seen with pharmacotherapy alone [1]. Noom is not a replacement for in-person metabolic care and does not offer lab draws, EKG monitoring, or the kind of multidisciplinary oversight found in academic obesity programs.

What Licenses and Oversight Apply?

Noom Med operates through a network of licensed nurse practitioners and physicians who are individually licensed in the states where they prescribe. The platform must comply with DEA telehealth rules and applicable state medical board regulations. Prescriptions for GLP-1 receptor agonists are not controlled substances, so the Ryan Haight Act restrictions that apply to stimulants do not apply here.

How Noom Differs From a Clinical Obesity Program

A hospital-based obesity program typically includes registered dietitian visits, behavioral health services, exercise physiology consults, and close lab monitoring. Noom provides none of those in-person services. What it does offer is scalable digital coaching at a lower per-session cost, which may suit patients who want behavioral support alongside a clinician-prescribed GLP-1 but who do not have access to a local obesity medicine specialist.

How Noom's Intake and Prescription Process Works

The intake is fully digital and asynchronous. No live video appointment is required at the start, which is both a convenience and a limitation.

Step 1: The Online Questionnaire

After creating an account, prospective patients complete a health history questionnaire covering current weight, height, past medical history, current medications, and any contraindications to GLP-1 therapy. Contraindications screened for include a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, pancreatitis history, and severe gastrointestinal disease. The FDA label for semaglutide (Ozempic, Wegovy) lists these as contraindications or warnings that require clinician judgment [2].

Step 2: Clinician Async Review

A Noom Med clinician reviews the submitted questionnaire, typically within one to two business days. If the clinical picture is appropriate, the clinician issues a prescription electronically to a pharmacy of the patient's choice or to a pharmacy partner. There is no guaranteed same-day prescribing.

Step 3: Eligibility Criteria

Noom Med generally follows the FDA-approved eligibility thresholds for GLP-1 medications. For injectable semaglutide (Wegovy), FDA approval covers adults with a BMI of 30 or higher, or BMI of 27 or higher with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or dyslipidemia [3]. Oral semaglutide (Rybelsus) carries a different labeled indication focused on type 2 diabetes glycemic control, so its off-label use for weight loss requires careful clinician judgment.

Step 4: Ongoing Monitoring

After the initial prescription, follow-up is conducted through the app and via messaging with the assigned clinician. Noom does not mandate in-person lab work, though clinicians may recommend it. This is a meaningful gap: the American Association of Clinical Endocrinology (AACE) 2023 obesity guidelines state that patients on GLP-1 therapy should have baseline metabolic panels and periodic follow-up labs to monitor for adverse effects and comorbidity management [4].

What GLP-1 Medications Does Noom Prescribe?

Noom Med has offered both oral and injectable semaglutide depending on state availability and clinician assessment. The field has shifted over time, particularly as compounded semaglutide availability changed following FDA actions on the shortage list.

Oral Semaglutide (Rybelsus)

Rybelsus is FDA-approved at doses of 3 mg, 7 mg, and 14 mg for type 2 diabetes management [2]. Weight loss data for oral semaglutide is available from the OASIS-1 trial, in which oral semaglutide 50 mg (a higher investigational dose not yet commercially available) produced 15.1% mean body weight reduction at 68 weeks versus 2.4% placebo [5]. The commercially available 14 mg dose produces more modest weight loss, generally in the 4 to 5% range in published studies, which is considerably less than the injectable 2.4 mg weekly dose.

Injectable Semaglutide (Wegovy)

The STEP-1 trial (N=1,961) demonstrated that subcutaneous semaglutide 2.4 mg once weekly produced a mean weight loss of 14.9% over 68 weeks versus 2.4% in the placebo group (P<0.001) [6]. This remains the most robustly studied GLP-1 dose for chronic weight management in adults without diabetes. Noom Med may prescribe Wegovy where available and clinically appropriate, though drug shortages and insurance coverage gaps have created access variability.

Tirzepatide (Zepbound)

As of mid-2024, Noom Med began offering tirzepatide (Zepbound) in select states. The SURMOUNT-1 trial (N=2,539) showed tirzepatide 15 mg produced 20.9% mean weight loss at 72 weeks versus 3.1% placebo (P<0.001) [7]. Whether Noom clinicians prescribe tirzepatide depends on patient eligibility and state-specific formulary availability.

Compounded Semaglutide: A Caution

During FDA-declared shortages, some telehealth platforms prescribed compounded semaglutide. The FDA removed semaglutide from the shortage list in February 2025, which means compounding pharmacies are no longer permitted to produce copies of Ozempic or Wegovy under the 503A/503B exemptions [8]. Patients should verify that any semaglutide prescription they receive from Noom or any platform is for an FDA-approved branded product, not a compounded version.

How Noom's Coaching Layer Works Alongside Medication

Behavioral support is a real component of obesity treatment outcomes. A meta-analysis in Obesity Reviews found that combining pharmacotherapy with structured behavioral intervention produced 3 to 5% additional weight loss compared to medication alone [9]. Noom's coaching is delivered through in-app messaging rather than synchronous video, which limits depth of therapeutic interaction but increases accessibility.

What Coaches Are and Are Not

Noom coaches are not registered dietitians, licensed clinical social workers, or physicians. They are trained Noom employees who follow structured coaching protocols. Patients with complex psychiatric histories, eating disorders, or significant medical comorbidities should seek care from licensed professionals rather than relying on Noom coaching as their primary behavioral support.

The App's Cognitive Behavioral Content

The Noom app delivers daily lessons built on cognitive behavioral therapy (CBT) and acceptance-based principles. CBT for weight management has a reasonable evidence base: a systematic review in JAMA Internal Medicine found CBT-based interventions produced 5 to 10% weight loss maintenance at 12 months in structured clinical trials [10]. App-delivered CBT has smaller effects, but it reaches patients who would not otherwise access in-person therapy.

Coaching Response Times

Noom coaches typically respond within 24 hours on weekdays. This is not crisis support and is not appropriate for patients experiencing mental health emergencies or acute medication side effects. Side effects from GLP-1 medications, including nausea, vomiting, and the less common but serious risk of acute pancreatitis, require prompt medical attention and should be directed to a clinician, not a coach.

Noom vs. Alternatives: A Direct Comparison

Several competing telehealth platforms offer GLP-1 prescribing with varying levels of clinical rigor, coaching depth, and cost transparency.

Noom vs. Hims and Hers Weight Loss

Hims and Hers prescribes GLP-1 medications through licensed clinicians and has offered compounded semaglutide at lower price points. Noom differentiates on behavioral coaching infrastructure. Neither platform provides in-person care. Patients who primarily want a GLP-1 prescription with minimal behavioral support may find Hims and Hers lower cost; patients who want structured daily behavioral content may prefer Noom's app.

Noom vs. WeightWatchers (WW) Clinic

WeightWatchers rebranded its clinical service as WW Clinic and offers GLP-1 prescribing alongside its points-based food tracking system. Like Noom, it is an asynchronous model. Noom's CBT-based curriculum is more psychologically structured; WW's food tracking system has a longer evidence record for modest weight loss in non-pharmacotherapy settings [11].

Noom vs. Found

Found Health combines prescribing of multiple medication classes (GLP-1s, bupropion/naltrexone, metformin) with coaching. It is more medication-flexible than Noom, which leans heavily on semaglutide options. The Obesity Medicine Association guidelines note that combination pharmacotherapy may benefit patients who do not respond adequately to GLP-1 monotherapy [12].

Noom vs. Traditional Obesity Medicine Clinic

An in-person obesity medicine specialist visit typically includes a comprehensive metabolic workup, dietitian referral, exercise prescription, and full medication review. Noom cannot replicate that depth. For patients with BMI above 40, significant comorbidities, or prior bariatric surgery, an in-person specialist is the appropriate standard of care.

What Does Noom Cost and Is It Worth It?

Cost is one of the most common concerns among prospective Noom users, and the total price is higher than the headline app subscription suggests.

App Subscription Pricing

The core Noom app subscription costs approximately $60, $70 per month on a monthly plan, with discounts for 4-month or annual commitments. Some users pay as little as $20, $30 per month on an annual plan. The coaching app alone does not include any medication or prescribing services.

Noom Med Add-On Cost

Noom Med charges a separate monthly fee for clinician access and prescribing services, which has been reported at roughly $49, $99 per month depending on the plan. This is in addition to the app subscription cost. Medication costs are then on top of that.

GLP-1 Medication Costs

Wegovy carries a list price of approximately $1,349 per month without insurance. Rybelsus lists at approximately $900 per month without insurance. Insurance coverage depends on individual plan formularies. The Inflation Reduction Act did not cap GLP-1 costs for weight loss (only for type 2 diabetes in Medicare Part D contexts) [13]. Patients should verify their specific coverage before starting.

Is the Total Cost Justified?

For a patient who would otherwise pay out of pocket for both a GLP-1 medication and a behavioral program, Noom's bundled approach may offer convenience. Whether the behavioral coaching produces clinically meaningful additive value above the GLP-1 alone depends on individual engagement. The STEP-5 trial (N=304) showed that semaglutide 2.4 mg maintained 15.2% weight loss at 104 weeks even with minimal behavioral counseling [14], which suggests that medication is the primary driver of outcome in highly adherent patients.

Clinical Limitations and Red Flags to Know Before Starting

Noom operates within the law and employs licensed clinicians. Still, the platform has limitations that patients and referring clinicians should understand clearly.

No Lab Monitoring Protocol

Noom does not require baseline or follow-up labs as a condition of prescribing. The Endocrine Society's 2023 obesity pharmacotherapy statement recommends monitoring thyroid function, lipid panels, and renal function in patients starting GLP-1 therapy who have relevant comorbidities [15]. Patients using Noom should arrange lab monitoring through their primary care clinician independently.

Asynchronous-Only Model for Serious Concerns

Because there are no mandatory synchronous clinical visits, a patient experiencing significant side effects may wait 24 to 48 hours for a clinician response through the app. Anyone experiencing severe abdominal pain, persistent vomiting, or signs of gallbladder disease while on a GLP-1 should go to an emergency department, not message a telehealth app.

Coaching Scope Limitations

As the American Society for Metabolic and Bariatric Surgery notes, patients with binge eating disorder or other clinical eating disorders require specialized treatment that goes beyond behavioral coaching delivered through an app [16]. Noom's intake questionnaire screens for some psychiatric history but is not a validated eating disorder diagnostic instrument.

Noom Reviews: What Real Patients Report

Published user reviews on third-party platforms show a consistent pattern. The behavioral app earns moderate satisfaction scores for daily content and accountability. Complaints cluster around billing clarity, cancellation difficulty, and variability in coaching quality. The Noom Med prescribing service has received mixed feedback regarding response times and the asynchronous model's limitations.

A 2022 study in JMIR mHealth and uHealth (N=225 Noom users) found a mean weight loss of 5.6% at 6 months among users who completed at least 75% of app lessons [1]. Completers represent a self-selected population; real-world completion rates for digital behavior change programs are generally low. Drop-off rates above 50% within the first 90 days are common in commercial app programs, a pattern observed across the app-based intervention literature.

The Federal Trade Commission has previously issued guidance on telehealth platforms making weight loss claims without adequate substantiation [17]. Noom has faced prior legal scrutiny over its billing and subscription cancellation practices, resulting in a 2023 settlement. Patients should read the subscription terms carefully before enrolling.